Phase 3Status unknownAge-related condition

Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis

A Randomized,Double Blind,Active Controlled Parallel Arm Multicenter Study Comparing Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Denosumab of Intas Pharmaceutical Limited (60 mg/mL) With Prolia® in Postmenopausal Women With Osteoporosis

Sponsor
Lambda Therapeutic Research Ltd. (Industry)
Enrollment
552 planned
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab; Denosumab-Ref
Ages
adults, older adults
Registry
NCT05419427, CTRI-2021-09-036190

Full record on ClinicalTrials.gov

From the registry

Denosumab of Intas is biosimilar denosumab candidate under development by Intas Pharmaceutical Limited (Biopharma Division). Denosumab of Intas is already approved by Indian drug licensing authority- Drug Controller General (India) for marketing in Indian population since 2018.As per regulatory requirement, a comparative clinical study to establish Pharmacokinetic, Pharmacodynamic and Immunogenicity equivalence is required to conclude therapeutic equivalence to obtain marketing authorization of a biosimilar investigational product. This is a multicenter, randomized, double-blind, active controlled study in approximately 552postmenopausal women with osteoporosis. An extension of the study is planned after completion of the initial 1 year of treatment. This extension is with the objective of submitting data on safety, and Immunogenicity, after switching of Prolia treatment arm to either Prolia or Intas denosumab for 6 months. This switching data is applicable only for FDA submission. Only patients who have undergone PK assessment will be eligible for the extension phase.

Primary outcomes

  • Maximum measured concentration after first dose of denosumab and denosumab-ref., ,
  • Area under the concentration versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method between denosumab and denosumab-ref postmenopausal women with osteoporosis
  • Area under the concentration versus time curve from time zero to infinity. Where AUC 0-∞= AUC0-t + Ct2, Ct is the last measurable concentration and t2 is the terminal rate constant

History

  1. Study completion

  2. Primary completion

  3. Last registry update

  4. Registered

  5. Started